Evidence map›Paper›PMID 40442132›Full record

ArticleNPJ breast cancer2025

Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.

Jasper J L van Geel, Elisabeth M Jongbloed, Jasmine Moustaquim, Gonneke van der Schoor, A Elise van Leeuwen-Stok, Marcel Smid, Carolien H M van Deurzen, Saskia M Wilting, Jelle Wesseling, Gabe S Sonke and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jasper J L van Geel *Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
Elisabeth M Jongbloed *Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jasmine MoustaquimDepartment of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
Gonneke van der SchoorDutch Breast Cancer Research Group (BOOG), Utrecht, The Netherlands.
A Elise van Leeuwen-StokDutch Breast Cancer Research Group (BOOG), Utrecht, The Netherlands.
Marcel SmidDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Carolien H M van DeurzenDepartment of Pathology, Erasmus MC, Rotterdam, The Netherlands.
Saskia M WiltingDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Jelle WesselingDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Gabe S SonkeDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
John W M MartensDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Carolina P SchröderDepartment of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands. c.schroder@nki.nl.

Funding

KWF Kankerbestrijding 2013-6267 (to Rijksuniversity Groningen)
6 · The paper itself

Abstract

Inflammatory breast cancer (IBC) is rare, with challenging diagnostics and unfavorable outcomes. Therefore, more molecular insight into IBC is needed. The comprehensive Dutch prospective INFLAME registry related IBC follow-up and treatment to histopathology and molecular analysis. Of consecutive patients, nationwide identified with newly diagnosed IBC, clinicopathological, treatment and outcome data were collected. Histopathology and RNA-sequencing were related to outcome. 125 IBC patients were enrolled. Forty-one (34%) patients had HER2 + , and 31 (25%) had triple-negative IBC. The estimated 3-year OS was 78% in M0 IBC and 29% in M1. PFS was worst in triple-negative IBC (median 7.9 vs 16.3 and 15.8 months in M1 HER2+ and HR + /HER2- IBC). DFS and OS in M0 IBC were better with guideline-concordant trimodal therapy than without (HR 0.15 and 0.15; p = 0.000005 and 0.00038). The unique prospective INFLAME confirms unfavorable IBC characteristics and outcomes. International efforts may support guideline adherence and identify IBC-specific targets.

Identifiers

PMID40442132
PMCPMC12122667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.